In the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method of ~~Use of~~ using a mutant ~~form~~ of EtxB or CtxB ~~to deliver~~ comprising delivering an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.

2. (Currently amended) The method of ~~Use according to~~ claim 1 wherein the agent is selected from the group consisting of a peptide or protein of interest (POI~~);~~), an antigen~~,~~, an antigenic determinant~~,~~, an antibody~~,~~, and a nucleotide sequence of interest (NOI).

3. (Currently amended) The method ~~Use~~ according to claim 2 wherein the agent ~~may be~~is linked to a membrane translocating or fusigenic peptide.

4. (Currently amended) The method ~~Use~~ according to claim 3 wherein the membrane translocating or fusigenic peptide ~~may~~ comprises elements of the Pol-loop segment corresponding to a domain in the C-terminal region of HSV-1 polymerase.

5. (Currently amended) The method ~~Use~~ according to claim 2, ~~3 or 4~~ wherein the antigen is selected from the group consisting of a viral antigen, a bacte-

rial antigen, a parasitic antigen; and a ~~tumour~~tumor associated antigen (TAA).

6. (Currently amended) The method ~~Use~~ according to ~~any one of claims 1-5~~ claim 1 wherein the agent is delivered into a vesicular compartment of the target cell.

7. (Currently amended) The method ~~Use~~ according to ~~any one of claims 1-6~~ claim 1 wherein the target cell comprises at least one constituent selected from the group consisting of cytosol, nucleus, and organelle, and wherein the agent is targeted to the cytosol and/or the nucleus and/or an organelle of the target cell.

8. (Currently amended) The method of claim 1 ~~Use according to any one of the preceding claims~~ wherein the target cell is an antigen presenting cell (APC).

9. (Currently amended) The method of claim 1 ~~Use according to any one of the preceding claims~~ wherein the mutant comprises a mutation in the region spanning amino acid residues E51-I58 of the β4-α2 loop of CtxB or EtxB.

10. (Currently amended) The method of claim 9 ~~Use according to claim 9~~ wherein the mutant comprises a mutation at amino acid residues 51, 56 and/or 57 of the β4-α2 loop.

11. (Currently amended) The method ~~Use according to~~ of claim 9 or claim 10 wherein the mutant comprises a H57A or H57S mutation.

12. (Currently amended) A method of ~~Use of~~ preparing a medicament comprising providing a mutant of EtxB or CtxB ~~according to any one of the preceding claims~~ in the preparation of a medicament ~~to~~, wherein the mutant is capable of delivering an exogenous peptide into the MHC Class I antigen processing and presentation pathways to elicit a CTL response.

13. (Currently amended) ~~Use~~ The method according to claim 12 wherein the exogenous peptide is ~~any one of the agents as defined in claim 5.~~an agent selected from the group consisting of a peptide or protein of interest (POI), an antigen, an antigenic determinant, an antibody, and a nucleotide sequence of interest (NOI).

14. (Currently amended) A method of using ~~The use of~~ a mutant of EtxB or CtxB for separate, simultaneous or combined use to treat a disease or a condition in a subject in need of same comprising ~~as defined in any one of claims 1-13 in the preparation of~~ administering a medicament comprising a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB. ~~for separate, simultaneous or combined use to treat a disease or a condition in a subject in need of same.~~

15. (Currently amended) A method of treating a disease or condition in a subject in need of same wherein the method comprises:

(i)_____providing a target cell; and

(ii) delivering an agent to the target cell using a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.~~as defined in any one of claims 1-13.~~

16. (Currently amended) A method according to claim 15 ~~or the use according to any one of claims 12-14~~ wherein the disease or condition is a viral infection or a cancer.

17. (Currently amended) A method of delivering an agent using a mutant to a target cell wherein the method comprises:

(i) providing a target cell;

(ii) contacting the cell with a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB~~the mutant as defined in any one of claims 1-13~~; and

(iii) monitoring for the presence of the agent in the target cell.

18. (Original) A method according to claim 17 wherein the agent is delivered to a vesicular compartment, and/or cytosol and/or nucleus and/or an organelle of the target cell.

19. (Currently amended) A composition, preferably a pharmaceutical composition, comprising a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB ~~as defined in any one of claims 1-13~~ and at least one pharmaceutically acceptable constituent selected from the group consisting of ~~carrier(s)~~, diluent~~(s)~~, excipient~~(s)~~ or adjuvant ~~or any~~and combinations thereof.

20. (Currently amended) A composition comprising a mutant as defined in any one of ~~claims 1-13~~claim 19 which is a vaccine.

21. (Currently amended) A kit for delivering an agent to a target cell wherein the kit comprises:

(i) a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB~~as defined in any one of claims 1-13~~;

(ii) an agent for delivery to the target cell; and optionally

(iii) means for detecting the location of the agent in the target cell.

22. (cancelled) ~~The use and the method substantially as defined herein and with reference to the accompanying Figures.~~

23. (New) The method according to claim 12 wherein the agent is linked to a membrane translocating or fusigenic peptide.

24. (New) The method according to claim 23 wherein the membrane translocating or fusigenic peptide comprises elements of the Pol-loop segment corresponding to a domain in the C-terminal region of HSV-1 polymerase.

25. (New) The method according to claim 13, wherein the antigen is selected from the group consisting of a viral antigen, a bacterial antigen, a parasitic antigen; and a tumor associated antigen (TAA).